Breaking: Sana Biotechnology Announces Public Offering of Common Stock

Sana Biotechnology, Inc., a leading player in the field of cell medicine, has initiated a public offering of $125 million of its common stock. The offering includes plans to grant the underwriters an option to purchase additional shares worth up to $18.75 million within a 30-day period. The joint book-running managers for the offering include some of the biggest names in global finance: Morgan Stanley, J.P. Morgan, Goldman Sachs & Co. LLC, and BofA Securities.

Offering Subject to Market Conditions and Other Factors

The offering is contingent on a variety of factors, including market conditions. At this stage, there is no certainty regarding the timing or the final terms. Details about the offering will be included in a preliminary prospectus supplement that will be filed by Sana. Interested parties can access these documents through the SEC’s website or directly from the managing banks.

Regulatory Compliance and Legal Obligations

This offering is being conducted under a Registration Statement on Form S-3 and a base prospectus that have already been filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus have also been filed, and a final version will be submitted to the SEC. These documents can be obtained for free from the SEC’s website. When the final prospectus supplement is available, it can also be obtained from the respective investment banks.

Forward-Looking Statements and Risks

The press release from Sana Biotechnology includes forward-looking statements. These are subject to risks and uncertainties, including the completion and terms of the offering, market conditions, economic factors, and geopolitical developments. The company does not undertake any obligation to update these statements in the future. It is also worth noting that this press release does not constitute an offer to sell or a solicitation of an offer to buy. No sale will occur in any jurisdiction where such a transaction would be unlawful before registration or qualification under the local securities laws.